ScienceNot yet confirmed elsewhere1 publisher2 min readPublished
Epilepsy drug lacosamide pushes damaged cartilage toward repair in Yale's preclinical osteoarthritis work
Yale researchers report that lacosamide, an FDA-approved epilepsy drug, eased joint pain and reversed cartilage damage in preclinical osteoarthritis studies. No FDA-approved medicine yet does both for osteoarthritis, so the open question is whether the effect holds in people.
The Scientist · Science desk
What happened
- The team targeted Nav1.7, a sodium channel long thought to act mainly in pain nerves, which Liu's group found is highly active in the chondrocytes that maintain cartilage.
- Nav1.7 is relatively quiet in healthy joints, but in osteoarthritis its activity rises substantially, amplifying pain signals and pushing chondrocytes to break cartilage down.
- Of the existing sodium-channel blockers tested, lacosamide acted at considerably lower concentrations and had a better safety profile than older drugs in its class.
- The effects were strongest when the drug was injected directly into the joint in a hydrogel built to hold it there, according to the study in Bioactive Materials.
Why it matters
- constraint Because the cartilage benefit appeared at a low ideal concentration, lacosamide's epilepsy dosing cannot simply be reused, and an osteoarthritis dose would have to be found separately.
- decision Developers would be taking a joint-injected gel formulation into trials, and the gel needs safety testing that lacosamide's epilepsy record does not cover.
- capability If the effect holds in people, patients would have a pain treatment that does not rely on addictive opioids and also acts on cartilage loss.
Standard osteoarthritis care treats symptoms. Over-the-counter painkillers and steroid injections can ease pain for a time, but they do not stop the underlying joint damage from progressing [9]. Advanced disease can end in a total knee replacement [14]. "There is a major unmet need in osteoarthritis," said Chuan-Ju Liu, the study's principal investigator and Yale's Charles W. Ohse Professor of Orthopaedics & Rehabilitation [10][12]. "We need therapies that don't just mask pain but actually change how the disease progresses." [10]
Liu's case rests on one channel doing two jobs. "When Nav1.7 becomes dysregulated, it contributes to both joint degeneration and pain," he said [11]. "By blocking this single protein, we can potentially quiet the pain nerves and tell the cartilage cells to not only stop breaking down but start repairing as well." [11]
I think the dose response is the most useful detail in Yale's account. Lacosamide's effect on cartilage depended heavily on concentration, and more drug was not necessarily better [7]. At an ideal low concentration it led cells to make proteins involved in building cartilage while suppressing the processes that break tissue down [7]. That describes what cells were doing; measurably more cartilage in a joint and less pain in a patient are further steps.
A low optimum is also a reasonable thing to see from a drug acting on a channel that is overactive in disease. My guess is that too little leaves the channel running, and too much may disturb cells that need some of its activity.
The release attributes the findings to preclinical studies [2]. It did not disclose which models were used, how many joints were treated, what the control groups received, how much cartilage was restored, or what happened above the ideal concentration. Those figures would show whether "reversing cartilage damage" describes a shift in cell behaviour or a measurable gain in joint tissue [1].
What to watch
- Whether the Bioactive Materials paper reports which preclinical models were used, the group sizes and controls, and a quantified measure of cartilage restored.
- What happened to cartilage cells when lacosamide was given above its ideal low concentration.
- Any move by Yale or a partner to take a joint-injected lacosamide hydrogel into a human trial, and the dose it selects.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence30
- Adoption
- Insufficient
- Hype gap+40
- Incentives65
- Confidence35
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
A Yale study published in Bioactive Materials found that lacosamide can reduce joint pain in osteoarthritis while also reversing cartilage damage.
- [2]
The effects of lacosamide on damaged joints were observed in preclinical studies.
- [3]
The effects were particularly strong when lacosamide was delivered directly into the joint using a specialized hydrogel designed to keep the drug inside the joint.
- [4]
Nav1.7 is a sodium channel long thought to operate primarily in nerve cells that transmit pain signals; work from Liu's team found it is also highly active in chondrocytes, the cells that maintain cartilage.
- [5]
Nav1.7 is relatively quiet in healthy joints, but in osteoarthritis its activity increases substantially, intensifying pain signaling and pushing chondrocytes toward breaking down cartilage.
- [6]
Liu's team tested existing drugs that inhibit sodium channels; lacosamide produced strong biological effects at considerably lower concentrations and offered a better safety profile than older drugs in the same class.
- [7]
Lacosamide's effects on cartilage depended heavily on dose; more was not necessarily better, and at an ideal low concentration it encouraged cells to produce proteins involved in building cartilage while suppressing processes that break tissue down.
- [8]
No medicine approved by the U.S. Food and Drug Administration can both stop osteoarthritis pain and prevent the structural breakdown of cartilage.
- [9]
Common osteoarthritis treatments, including over-the-counter medications and steroid injections, may reduce symptoms for a time but do not prevent the underlying joint damage from progressing.
- [10]
"There is a major unmet need in osteoarthritis. We need therapies that don't just mask pain but actually change how the disease progresses."
- [11]
"When Nav1.7 becomes dysregulated, it contributes to both joint degeneration and pain. Our findings suggest that Nav1.7 is a dual-acting target. By blocking this single protein, we can potentially quiet the pain nerves and tell the cartilage cells to not only stop breaking down but start repairing as well."
- [12]
Chuan-Ju Liu, PhD, is the study's principal investigator and Charles W. Ohse Professor of Orthopaedics & Rehabilitation at Yale.
- [13]
Lacosamide is an FDA-approved drug already used to treat epilepsy.
- [14]
In osteoarthritis, cartilage breaks down faster than chondrocytes can replace it; as the disease advances, some patients may require joint reconstruction such as a total knee replacement.
- [15]
The approach could potentially preserve joint tissue while delivering sustained pain relief without relying on addictive opioids.
Sources
1 independent publisher whose own reporting we read for this story.
- sciencedaily.comFDA-approved epilepsy drug may help reverse osteoarthritis damage
1 article · October 8, 2026
Topics and entities
Follow any of these and your For You feed starts watching them — no settings page required.
Topics
- OsteoarthritisFollow
- Drug RepurposingFollow
- Intra-articular drug deliveryFollow
Entities
- LacosamideFollow
- Nav1.7Follow
- Yale School of MedicineFollow
- Chuan-Ju LiuFollow
- Bioactive MaterialsFollow
- US Food and Drug AdministrationFollow